Panzyga
ApprovedSmall molecule
OctapharmaPanzyga is one of 93 small molecule programs targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy. It is currently in Approved.
3
Indications
5
Total Trials
1
Active Trials
92
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
367 competitors in Chronic Lymphocytic Leukemia
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Venclexta
AbbViePhase 3
Gazyva
RochePhase 3
Calquence
AstraZenecaPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Nipent
PfizerPhase 3
Brukinsa
BBeOne Medicines
Phase 3
Medrol
PfizerPhase 3
Adcetris
PfizerPhase 3
Beqalzi
BBeOne Medicines
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pediatric1 trial
Immune Thrombocytopenia1 trial
Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial
Chronic Lymphocytic Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Panzyga. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company